InvestorsHub Logo
icon url

genisi

10/30/10 3:37 PM

#603 RE: genisi #592

Shire booked sales of $50M for Vpriv (velaglucerase for Gaucher) in Q3, a 71% growth over Q2. Currently treating about 1,000 patients.